



Group Model Effectiveness Review – Year One 2021/22

NHFT Foundation Trust Board of Directors 24 November 2022 / LPT Trust Board of Directors 29 November 2022

Purpose of the report

An annual update on the effectiveness of the Group Model containing information to be presented to both LPT and NHFT Trust Boards in November 2022 including;

- A. Review of outputs from strategic programmes year 1.
- B. Recommended strategic programmes year 2
- C. A review of effectiveness of the Joint Working Group (JWG) year 1 2021/22.
- D. Appended updated Group Model Memorandum of Understanding (MoU), Committees in Common (CiC) Terms of Reference (ToR) and JWG ToR for 2022/23
- E. Proposal for the identification of further opportunities for 2022/23

Analysis of the issue

A. Outputs from Year 1 2021/22

When Leicestershire Partnership and Northamptonshire Healthcare Group was created, the Trust Boards each approved a three-year programme of strategic programmes to be overseen by the Committees in Common via the Joint Working Group.

Good progress has been achieved within the strategic programmes for year one, with 70% of plans rated as green with all year one objectives delivered. The remaining 30% of plans had partially delivered year one objectives, with one or more ongoing or carried forward into year two.

Strategic Programmes	Status	Main Achievements				
Research and Innovation	Amber. Year 1 objectives	- Advertised joint Head of R&I Innovation post				
Research and innovation	partially complete	- Identified need for a Group research mechanism.				
		- Clinical trials				
		- A joint footprint for medical education				
Governance	Green. All year 1	- Group Model and CiC/JWG blueprint				
Governance	objectives complete	- Formalised joint governance meetings				
		- SEB/EMB structure for executive team meetings				
		- LPT 2021 Well Led review by the CQC complete, rating				
		increased to 'Requires Improvement' with elements of good.				
Together Against Racism	Green. All year 1	- BAME Aligned Talent Management programmes				
Tugether Against Nacisin	objectives complete	- TAR agreed actions				
		- Joint Board Workshop 21 November 2022				
Leadership and OD	Green. All year 1	- Leading Remote Teams with learning and feedback				
Leadership and OD	objectives complete	- Leadership Masterclasses				
Talent Management	Amber. Year 1 objectives	- Talent Management Boards				
Talent Management	partially complete	- Joint learning/networking opportunities				
		- Mentoring Programme				
		- A set of "Free movement of talent" enablers				
Quality Improvement	Amber. Year 1 objectives	- Single quality strategy approach discussed				
	partially complete	- Shared director of patient safety post developed.				
		- Improvement Knowledge Hub development				
		- Process for prioritising QI projects				
		- Developed a strategic business case to further strengthen the				
		IKH workforce				

Table 1 Year One outputs





Finance Leadership	Green. All year 1 objectives complete	-	Benchmarking progress PLICS SYNERGY costing systems Value Based Healthcare approach Provider Collaborative financial approach
Estates	Green. All year 1 objectives complete	-	Green Plan documents to Trust Boards

B. Strategic Programmes for Year 2 recommended by the JWG

In year one, the Trust Boards approved eight strategic programmes for the Group. The eight strategic priority programmes remain in place as detailed below and are in year two of a three-year delivery programme;

- Governance
- Together Against Racism extended to reflect a wider priority for Equality, Diversity and Inclusion from year 2
- Leadership and OD
- Talent Management
- Quality Improvement
- Finance Leadership
- Estates
- Research and Innovation

C. Effectiveness of the JWG – year 1 (2021/22)

Attendance and quoracy

The JWG has been quorate for each meeting throughout the year, with the following attendance rates from each member detailed below in Table 2;

Attendance	April 21	Jun 21	Aug 21	Sept 21	Nov 21	Dec 21	Jan 22	Mar 22	Attendance rate %
NHFT Trust Chair – Crishni Waring	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Business completed via email due to COVID pressures (not	\checkmark	100%
LPT Trust Chair – Cathy Ellis	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	100%
Joint Chief Executive - Angela Hillery	\checkmark	\checkmark	Х	\checkmark	\checkmark	\checkmark		\checkmark	86%
NHFT Deputy Chief Exec - David Maher	\checkmark	\checkmark	Х	\checkmark	\checkmark	\checkmark		\checkmark	86%
LPT Deputy Chief Exec – Mark Powell	\checkmark	\checkmark	Х	\checkmark	\checkmark	\checkmark	included in attendance	\checkmark	86%
NHFT Non-Executive Director - Maria Wogan	\checkmark	\checkmark	\checkmark	Х	\checkmark	Х	rate %)	\checkmark	72%
LPT Non-Executive Director – Ruth Marchington	\checkmark	Х	\checkmark	\checkmark	\checkmark	\checkmark		NA	72%
Director of Governance and Risk (LPT) and Director of HR and OD (NHFT) – Chris Oakes	\checkmark	Х	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	86%
Director of Strategy & Business Development, David Williams	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark	100%
Chief Finance Officer, Richard Wheeler (until Jan 2022)	\checkmark	Х	\checkmark	\checkmark	\checkmark	\checkmark		NA	83%
Chief Finance Officer, Paul Sheldon (from Jan 2022)	NA	NA	NA	NA	NA	NA		\checkmark	100%
NHFT Non-Executive Director – Moira Ingram (Until April 21)	\checkmark	NA	NA	NA	NA	NA		NA	100%





Feedback from members

In the main, members 'strongly agreed' or 'agreed' with the statements over the effectiveness of the JWG. One area highlighted by a number of comments related to the administration of the meeting – largely the need to schedule meetings further ahead. There was also a recommendation that administration be normalised with other Board Committees, taken on by the corporate secretariat from Quarter 3 2022. This has been reflected in the JWG ToR (Appendix 3).



Proposal

D. Group Model Memorandum of Understanding, CiC ToR and JWG ToR

The LPT and NHFT Trust Boards have both individually reviewed key elements of the Group Model MoU at a Trust Board Development sessions, and were supportive of continuing the current arrangements for at least a further year based on the original wording set out in the MoU approved in March 2021, including;

- The principles of the Group Model
- The Committees in Common approach, utilising the Joint Working Group
- The key focus of the Committees in Common

Following review, an additional 'early termination' clause was proposed, and it was felt that there should be a greater overt emphasis on the role of sharing learning. With the Group focussed on synergies for the two organisations, it was also suggested that it is clarified within the MoU that there will be no adverse impact on either organisation, or on decision making within each organisation, as a result of these arrangements.

Minor changes have been proposed to the MoU (Appendix 1), the CiC ToR (Appendix 2) and the JWG ToR (Appendix 3) to reflect this annual review and the comments above, for approval by each Trust Board in November 2022.





NB these changes are shown in the appendices as tracked changes so as to make clear how the original text is proposed to change as a result of the effectiveness review.

E. Proposal for further opportunities in Year 2

In addition to the joint strategic programmes outlined above, the Group Model has continued to embrace opportunities to further realise the benefits of a combined approach to key strategic issues. We will continually be cognisant of and take opportunities to exploit advantage and sharing of best practice. This has included the introduction of joint roles which to date include a Director of Strategy and Partnerships and a joint Head of Patient Safety.

In year 2, we are looking to introduce further opportunities for improvement and development including clinical leadership, as part of the JWG we will also explore the potential for an underpinning strategic framework for the Group going forwards.

If any opportunities identified require a change in the MoU or the ToR for the CiC and JWG, these will be proposed by the JWG where appropriate and presented to both Trust Boards for approval.

Decisions required

Approval for the content of the paper including the JWG annual review of effectiveness, minor amendments to the Group Model MoU, CiC ToR and JWG ToR for 2022/23.





Governance Table

For Board and Board Committees:	NHFT Trust Board 24 November 2022 / LPT Trust Board 29					
	November 2022					
Paper sponsored by:	Chris Oakes, Director of Governance and Risk					
Paper authored by:	Kate Dyer, Deputy Director of Governance and Risk / Richard					
	Smith, Assistant Director of Corporate Governance					
Date submitted:	20 November 2022					
State which Board Committee or other forum	LPT-NHFT Committees in Common Joint Working Group 6					
within the Trust's governance structure, if any, have previously considered the report/this issue	Sept 2022					
and the date of the relevant meeting(s):						
If considered elsewhere, state the level of	LPT-NHFT Committees in Common Joint Working Group					
assurance gained by the Board Committee or other	HIGHLIGHT REPORT 6 th September 2022 High Assurance					
forum i.e. assured/ partially assured / not assured:	(Green)					
State whether this is a 'one off' report	Annual Review					
LPT STEP up to GREAT strategic alignment*:	High S tandards	Yes				
	Transformation	Yes				
	Environments	Yes				
	Patient Involvement	Yes				
	Well Governed	Yes				
	Reaching Out	Yes				
		Yes				
	Equality, Leadership, Culture Access to Services	Yes				
	Trust wide Quality	Yes				
	Improvement	res				
NHFT DIGB Q strategic alignment*:	Develop	Yes				
	Innovate	Yes				
	Grow	Yes				
	Build	Yes				
	Quality	Yes				
Organisational Risk Register considerations:	List risk number and title of risk	LPT – Reaching Out				
	List fisk humber and the of fisk	NHFT – Partnerships				
		Working				
Is the decision required consistent with LPT's	Yes					
risk appetite:						
False and misleading information (FOMI)	None					
considerations:						
Positive confirmation that the content does	Confirmed					
not risk the safety of patients or the public						
Equality considerations:	None					